4.7 Article

Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV

出版社

ELSEVIER
DOI: 10.1016/j.ijantimicag.2021.106492

关键词

HIV; Multidrug resistance; Heavily treatment-experienced people; Next-generation sequencing; Mutational load; APOBEC editing

资金

  1. ViiV Healthcare
  2. Theratechnologies

向作者/读者索取更多资源

The study found that heavily treatment-experienced individuals with multidrug-resistant HIV had high levels of drug resistance mutational load but less pronounced APOBEC editing. Patients who failed treatment showed higher levels of DNA resistance and mutational load compared to those who responded.
Background: The impact of drug resistance mutational load and APOBEC editing in heavily treatment-experienced (HTE) people living with multidrug-resistant HIV has not been investigated. Material and Methods: This study explored the HIV-DNA and HIV-RNA mutational load of drug resistance and APOBEC-related mutations through next-generation sequencing (NGS, Illumina MiSeq) in 20 failing HTE participants enrolled in the PRESTIGIO registry. Results: The patients showed high levels of both HIV-DNA (4.5 [4.0-5.2] log(10) copies/10(6) T-CD4+ cell) and HIV-RNA (4.5 [4.1-5.0] log(10) copies/mL) with complex resistance patterns in both compartments. Among the 255 drug-resistant mutations found, 66.3% were concordantly detected in both HIV-DNA and HIV-RNA; 71.3% of mutations were already present in historical Sanger genotypes. At an intra-patient frequency > 5%, a considerable proportion of mutations detected through DNA-NGS were found in historical genotypes but not through RNA-NGS, and few patients had APOBEC-related mutations. Of 14 patients who switched therapy, the five who failed treatment had DNA resistance with higher intra-patient frequency and higher DNA/RNA mutational load in a context of tendentially less pronounced APOBEC editing compared with those who responded. Conclusions: Using NGS in HIV-DNA and HIV-RNA together with APOBEC editing evaluation might help to identify HTE individuals with MDR who are more prone to experience virological failure. (C) 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Parasitology

Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage

Serena Marchi, Filippo Dragoni, Adele Boccuto, Olubukola T. Idoko, Maurizio Zazzi, Samba Sow, Aldiouma Diallo, Simonetta Viviani, Emanuele Montomoli, Ilaria Vicenti, Claudia Maria Trombetta

Summary: Genetic and phylogenetic studies have found that Zika virus (ZIKV) has two major lineages, African and Asian, but it is described as a single serotype. This study evaluated the cross-neutralization between ZIKV strains from the African and Asian lineages. The results showed that samples with neutralizing antibodies against the African lineage strain also had neutralizing activity against the Asian lineage strain, although with lower titers. The differences in neutralizing activity were attributed to approximately 120 amino acid differences between the two strains. However, all samples still had neutralizing antibody titers considered to be protective.

ACTA TROPICA (2023)

Article Infectious Diseases

Antibiotic appropriateness for Gram-negative bloodstream infections: impact of infectious disease consultation

Valentina Da Prat, Laura Galli, Paola Cichero, Barbara Castiglioni, Chiara Oltolini, Chiara Tassan Din, Andrea Andolina, Elena Bruzzesi, Andrea Poli, Matteo Moro, Nicasio Mancini, Massimo Clementi, Moreno Tresoldi, Antonella Castagna, Paolo Scarpellini, Marco Ripa

Summary: In a setting with high antibiotic resistance, IDC and RDTs are associated with earlier prescription of appropriate therapy in GNBSIs, without impact on mortality.

INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen

Rossana Scutari, Laura Galli, Claudia Alteri, Andrea Poli, Lorenzo Piermatteo, Alba Bigoloni, Carlo Federico Perno, Adriano Lazzarin, Francesca Ceccherini-Silberstein, Antonella Castagna, Maria Mercedes Santoro, Nicola Gianotti

Summary: This study investigated HIV-DNA and residual viremia levels over 96 weeks in virologically-suppressed HIV-1-infected individuals. The results showed a small reduction in HIV-DNA and RV levels at W96 in individuals who switched to the E/C/F/TAF arm compared to those who remained on the DTG + 1 RTI arm. However, there were no significant differences between the two arms in the changes in HIV-DNA and HIV-RNA over time.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Editorial Material Infectious Diseases

Comment on: Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study

Arturo Ciccullo, Gianmaria Baldin, Gaetana Sterrantino, Giordano Madeddu, Gabriella D'ettorre, Cristina Mussini, Simona Di Giambenedetto

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

Daniele Armenia, Maria M. Santoro, Charlotte Charpentier, Ada Bertoli, Federica Forbici, Vincent Calvez, Diane Descamps, Francesca Ceccherini-Silberstein, Anne-Genevieve Marcelin, Philippe Flandre

Summary: This study aimed to evaluate integrase resistance and its predictors in HIV-1 infected individuals who failed a dolutegravir-based antiretroviral therapy. Major resistance mutations and genotypic susceptibility score were analyzed. The results showed that INSTI resistance was low and mainly related to previous first-generation INSTI exposure. Monitoring integrase resistance is crucial to preserve the efficacy of INSTI class in the future.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Inflammation burden score in multidrug-resistant HIV-1 infection

Tommaso Clemente, Roberta Caccia, Laura Galli, Andrea Galli, Andrea Poli, Giulia Carla Marchetti, Alessandra Bandera, Maurizio Zazzi, Maria Mercedes Santoro, Paola Cinque, Antonella Castagna, Vincenzo Spagnuolo

Summary: This study measured inflammation, immune activation, and microbial translocation biomarkers in four-class drug-resistant (4DR) people living with HIV (PLWH). The results showed that 4DR-PLWH with detectable viremia had the highest biomarker concentrations. The study also found an association between viremia and increased expression of CD38/HLA-DR and PD-1 on CD4+ and CD8+ cells. Therefore, therapeutic approaches to reduce inflammation and T-cell exhaustion in 4DR-PLWH need to be investigated.

JOURNAL OF INFECTION (2023)

Article Medicine, General & Internal

CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases

Valeria Cento, Luna Colagrossi, Irene Bossi, Daniele Armenia, Alice Nava, Enrico Piccinelli, Alessandro Maloberti, Elvira Inglese, Elisa Matarazzo, Federica Di Ruscio, Pierpaolo Paba, Fabbio Marcuccilli, Marco Perrone, Gaetano Chiricolo, Claudia Alteri, Francesco Scaglione, Chiara Vismara, Daniela A. Campisi, Diana Fanti, Francesco Romeo, Massimo Andreoni, Fabrizio Oliva, Francesca Ceccherini-Silberstein, Cristina Giannattasio, Carlo F. Perno

Summary: This study aimed to investigate the role of cytomegalovirus (CMV) in acute coronary syndromes (ACS). The study found that CMV-IgG seroprevalence was high in patients with heart diseases, and the presence of CMV-DNA in coronary circulation may indicate the trigger of ACS. These results suggest that CMV may play a role in the development of ACS.

MINERVA MEDICA (2023)

Article Virology

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naive AIDS- or Late-Presenting HIV-Infected Patients

Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto

Summary: In this retrospective multicenter study, the efficacy and durability of dolutegravir and darunavir were compared in advanced naive patients with AIDS or late-presenting HIV infection. The results showed that there was no significant difference in treatment efficacy between dolutegravir and darunavir, but dolutegravir had a higher risk of central nervous system toxicity, while darunavir was more likely to lead to treatment simplification.

VIRUSES-BASEL (2023)

Article Immunology

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies

Lorenzo Piermatteo, Stefano D'Anna, Ada Bertoli, Maria Bellocchi, Luca Carioti, Lavinia Fabeni, Mohammad Alkhatib, Simone La Frazia, Miriam Lichtner, Claudio Mastroianni, Giuseppe De Sanctis, Massimo Marignani, Caterina Pasquazzi, Nerio Iapadre, Giustino Parruti, Giuseppina Cappiello, Jacopo Vecchiet, Vincenzo Malagnino, Sandro Grelli, Francesca Ceccherini-Silbertein, Massimo Andreoni, Loredana Sarmati, Valentina Svicher, Romina Salpini

Summary: 17.7% of HBV-D infected patients carry at least one vaccine-escape mutation, and the proportion of patients with complex mutations is increasing over time. Complex mutations are associated with lower HBsAg levels and HBsAg negativity despite HBV-DNA positivity.

EMERGING MICROBES & INFECTIONS (2023)

Article Immunology

SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naive and on Successful Antiretroviral Therapy

Ilaria Vicenti, Monica Basso, Nicole Pirola, Beatrice Bragato, Maria Cristina Rossi, Mario Giobbia, Susanna Pascoli, Antonio Vinci, Sara Caputo, Ilenia Varasi, Camilla Biba, Lia Fiaschi, Maurizio Zazzi, Saverio Giuseppe Parisi

Summary: This prospective observational study aimed to determine the response against the B.1 and BA.5 lineages in HIV-infected patients after the third BNT162b2 mRNA vaccine dose. The study found that all subjects had detectable neutralizing antibodies against B.1, but only 88 subjects had antibodies against BA.5. The titers of antibodies to B.1 were significantly higher than those to BA.5, and there was a strong positive correlation between the two.

VACCINES (2023)

Article Infectious Diseases

Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)

Barbara Rossetti, Francesca Incardona, Giulia Di Teodoro, Chiara Mommo, Francesco Saladini, Rolf Kaiser, Anders Sonnerborg, Thomas Lengauer, Maurizio Zazzi

Summary: The EuResist cohort, established in 2006, aims to develop a clinical decision-support tool for predicting the most effective antiretroviral therapy for HIV patients based on their clinical and virological data. It has expanded its activities to study antiretroviral treatment resistance and virus evolution. The cohort has retrospectively enrolled HIV patients from 1998 and released a treatment-response prediction system in 2008. With the support of artificial intelligence, EuResist will continue to investigate clinical response to antiretroviral treatment and monitor HIV drug resistance.

TROPICAL MEDICINE AND INFECTIOUS DISEASE (2023)

Article Infectious Diseases

Low-level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression

S. Elen, P. Bjorkman, M. Zazzi, M. Bohm, E. Bernal, A. Sonnerborg, O. Elvstam, EuResist Network Study Grp

Summary: This study aims to investigate the longitudinal patterns of viraemia in people with HIV and low-level viraemia (LLV) during antiretroviral therapy (ART) and identify factors associated with viral suppression. The results show that most people with LLV did not experience sustained viral suppression during the 24-month follow-up, which is associated with inferior treatment outcome.

HIV MEDICINE (2023)

Article Computer Science, Interdisciplinary Applications

Generating synthetic clinical data that capture class imbalanced distributions with generative adversarial networks: Example using antiretroviral therapy for HIV

Nicholas I-Hsien Kuo, Federico Garcia, Anders Soennerborg, Michael Boehm, Rolf Kaiser, Maurizio Zazzi, Mark EuResist Network study Grp, Mark Polizzotto, Louisa Jorm, Sebastiano Barbieri

Summary: This study proposes an extension to the GAN framework that incorporates a VAE and an external memory mechanism to overcome the limitations faced by GANs in healthcare. The proposed method generates synthetic data that accurately describe imbalanced class distributions commonly found in clinical variables, with low patient disclosure risk and high utility for downstream machine learning models.

JOURNAL OF BIOMEDICAL INFORMATICS (2023)

Article Virology

Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens

Joseph Fokam, Collins Ambe Chenwi, Valere Tala, Desire Takou, Maria Mercedes Santoro, George Teto, Beatrice Dambaya, Felix Anubodem, Ezechiel Ngoufack Jagni Semengue, Grace Beloumou, Sandrine Djupsa, Edgar Assomo, Charles Fokunang, Claudia Alteri, Serge Billong, Nounouce Pamen Bouba, Rogers Ajeh, Vittorio Colizzi, Dora Mbanya, Francesca Ceccherini-Silberstein, Carlo-Federico Perno, Alexis Ndjolo

Summary: This study described the patterns and factors influencing drug resistance in first-line antiretroviral therapy in Cameroon, and highlighted the poor efficacy of certain regimens in two regions of the country. The findings support the urgent need for a transition to NNRTI-sparing regimens, with TDF-3TC-DTG being recommended as the optimal option.

VIRUSES-BASEL (2023)

Article Virology

Frequency of Atypical Mutations in the Spike Glycoprotein in SARS-CoV-2 Circulating from July 2020 to July 2022 in Central Italy: A Refined Analysis by Next Generation Sequencing

Maria Concetta Bellocchi, Rossana Scutari, Luca Carioti, Marco Iannetta, Greta Marchegiani, Lorenzo Piermatteo, Luigi Coppola, Simona Tedde, Leonardo Duca, Vincenzo Malagnino, Lorenzo Ansaldo, Neva Braccialarghe, Stefano D'Anna, Maria Mercedes Santoro, Andrea Di Lorenzo, Romina Salpini, Elisabetta Teti, Valentina Svicher, Massimo Andreoni, Loredana Sarmati, Francesca Ceccherini-Silberstein, PTV UTV ID COVID Grp

Summary: In this study, the authors investigated the SARS-CoV-2 variants circulating in Italy and their association with viral load, N-glycosylation pattern, hospitalization, and vaccination. They found that different variants showed varying rates of hospitalization and that vaccination reduced the occurrence of atypical mutations. However, vaccinated individuals who required hospitalization had increased atypical variability. The study also identified a few samples with different N-glycosylation patterns, and minor atypical mutations were associated with higher viral load and longer duration of infection.

VIRUSES-BASEL (2023)

Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)